Back to News
Market Impact: 0.6
Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
Source: globenewswire.com
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
Priovant Therapeutics announced FDA approval of LISRAYA™ (brepocitinib) 30 mg for treating adults with dermatomyositis, with dosing as a once-daily pill. The approval is a major regulatory milestone that can materially improve the company’s commercial outlook and investor sentiment. Market impact is likely meaningful for the stock given the positive FDA action.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.85
More News
- Musk says Terrafab chip factory could outperform rivals despite challenges
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Will Warner Bros. kill Skydance — or will David Ellison kill Warner Bros?
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Cerebras Is About as Big as Nvidia's Data Center Business Was Nearly a Decade Ago. The Similarities Mostly End There.
- How U.S. know-how is fracking Australia into a gas boom, from Texas oilmen to Trump’s energy secretary